CompletedPhase 3NCT01243476
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fundación General de la Universidad de Salamanca
- Principal Investigator
- Consuelo del Cañizo, MDHospital Clínico Universitario de Salamanca
- Intervention
- Lenalidomide(drug)
- Enrollment
- 61 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2022
Study locations (25)
- Hôpitaux Universitaires de Strasbourg, Strasbourg, Bajo Rin, France
- Centre Hospitalier Universitaire de Nîmes, Nîmes, Gard, France
- Centre Hospitalier Régional d'Orléans, Orléans, Loiret, France
- Centre Hospitalier Universitaire d'Angers, Angers, Maine Y Loira, France
- Centre Hospitalier Universitaire Brabois, Nancy, Meurthe Y Mosel, France
- Centre Hospitalier d'Avignon, Avignon, Vaucluse, France
- Hôspital St. Louis, Paris, France
- Universitaetsklinikum Carl Gustav Carus der Technischen Universitaet Dresden, Dresden, Germany
- Marien Hospital Duesseldorf, Düsseldorf, Germany
- Klinikum rechts der Isar der Technischen Universität München, München, Germany
- Hospital Son Llàtzer, Palma de Mallorca, Balearic Islands, Spain
- Hospital Universitari Germans Trias i Pujol (ICO Badalona), Badalona, Barcelona, Spain
- Hospital de Cabueñes, Gijón, Principality of Asturias, Spain
- Hospital Central de Asturias, Oviedo, Principality of Asturias, Spain
- Hospital de Cruces, Barakaldo, Vizcaya, Spain
- +10 more locations on ClinicalTrials.gov
Collaborators
Celgene Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01243476 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.